Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-17
SponsorRennes University Hospital
About this trial
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Under 18 years
With established diagnosis of B-ALL
Initial diagnosis made in the investigating centre
Having received oral and written information about the protocol, or oral only if the patient is unable to read.
Disqualifiers
Isolated extramedullary involvement at inclusion
Patient of childbearing age without effective contraception.
Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Trial design
Design model
Single group
Treatments tested in this trial
Sampling bone tissue and blood
Other interventionExtra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: PatientsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Non coding RNA network in CD9 regulation
description of the network of lncRNAs (circRNAs/miRNAs) involved in the regulation of CD9 present on the surface of blasts at the time of diagnosis of B-ALL (nature of the lncRNAs, level of expression, etc.)
Time frame
5 yearsSecondary outcomes
1
Non coding RNA network in CD9 regulation as a prognosis factor of disease follow-up
Activity of the ncRNA (circRNA/miRNA) network regulating CD9 gene expression as a follow-up marker in CD9+ pediatric B-ALL.
Time frame
5 years2
Non coding RNA network in CD9 regulation as a predictive factor of relapse
Activity of the ncRNA (circRNA/miRNA) network regulating CD9 gene expression as a predictive marker of relapse in CD9+ pediatric B-ALL.
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov